Aktiv Pharma (“Aktiv” or “the Company”) is a pharmaceutical services and technology company that specializes in the drug delivery market. The company leverages a distinct vertically integrated organizational structure to deliver development support from start to finish for combination projects.

After a 5-year focus supporting U.S. government needs for the development and manufacturing of combination products and innovative container closure systems via a novel autoinjector platform, Aktiv has pivoted to the commercial biopharma market.

With over $60 million of non-dilutive capital from the US Government plus an additional $20 million of outside capital, Aktiv has amassed a unique set of assets and capabilities including a strong IP fortress consisting of 43 issued patents and 57 pending applications.

In addition to the autoinjector technology, Aktiv has also established a turnkey CDMO operation for autoinjector design/development, assembly, and sterile fill/finish.